| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 4 securities · passive | ||||||
|
Tango Therapeutics, Inc.
13G/A
TNGX · 87583X109
|
0% |
8/14/2026
Event 6/30/2026
|
||||
| Nextech Crossover I GP S.a. r.l. | 0% | |||||
| Nextech Crossover I SCSp | 0% | |||||
| Ian Charoub | 0% | |||||
| Costas Constantinides | 0% | |||||
| Rocco Sgobbo | 0% | |||||
|
Mersana Therapeutics, Inc.
13G/A
MRSN · 59045L205
|
0% |
1/9/2026
Event 1/6/2026
|
||||
| Nextech Crossover I GP S.a. r.l. | 0% | |||||
| Nextech Crossover I SCSp | 0% | |||||
| Ian Charoub | 0% | |||||
| Costas Constantinides | 0% | |||||
| Rocco Sgobbo | 0% | |||||
|
ORIC Pharmaceuticals, Inc.
13G/A
ORIC · 68622P109
|
8.4% |
8/14/2025
Event 6/30/2025
|
||||
| Nextech Crossover I GP S.a. r.l. | 8.4% | |||||
| Nextech Crossover I SCSp | 8.4% | |||||
| Ian Charoub | 8.4% | |||||
| Costas Constantinides | 8.4% | |||||
| Rocco Sgobbo | 8.4% | |||||
|
Mersana Therapeutics, Inc.
13G/A
MRSN · 59045L106
|
10.4% |
12/26/2024
Event 12/20/2024
|
||||
| Nextech Crossover I GP S.a. r.l. | 10.4% | |||||
| Nextech Crossover I SCSp | 10.4% | |||||
| Ian Charoub | 10.4% | |||||
| Costas Constantinides | 10.4% | |||||
| Rocco Sgobbo | 10.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.